Document is current
Any future updates will be listed below
-
Authors
Bhamra, Manvir
Harbottle, Zoe
Golding, Michael A
Ben-Shoshan, Moshe
Roos, Leslie E
Abrams, Elissa M
Penner, Sara J
St-Vincent, Jo-Anne
Protudjer, Jennifer LP https://orcid.org/0000-0002-3888-8688
-
Funding
Funding for this research was provided by:
Canadian Allergy, Asthma and Immunology Foundation (Canadian Allergy, Asthma and Immunology Foundation)
- License Information
-
More Information
Article History
Received: 4 May 2023
Accepted: 19 July 2023
First Online: 29 July 2023
Declarations
:
: ZH declares no real or perceived conflicts of interest. MB declares no real or perceived conflicts of interest. MG declares no real or perceived conflicts of interest. MB-S is part of the advisory Board or equivalent: Bausch, Stallergenes, Novartis, & Sanofi. Payment (including gifts or in-kind compensation) from a commercial organization: Bausch, Stallergenes, Novartis, Sanofi, & Stallergene. Participating or participated in a clinical trial: Novartis, Aimmune, & Sanofi. EMA declares no real or perceived conflicts of interest. LER declares no real or perceived conflicts of interest. SP declares no real or perceived conflicts of interest. JStV declares no real or perceived conflicts of interest. JP is Section Head, Allied Health, Canadian Society of Allergy and Clinical Immunology, and is on the steering committee for Canada’s National Food Allergy Action Plan. She reports consulting for Novartis, Nutricia and ALK Abelló.
: This study was approved by the University of Manitoba Health Research Ethics Board HS25168 (H2021:340).
: All authors have read and approved the submitted version of the manuscript.
